leadf
logo-loader
viewPharmaxis Ltd

Pharmaxis granted orphan drug designation for PXS‐5505 by FDA for treatment of myelofibrosis

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

Pharmaxis Ltd - Pharmaxis granted orphan drug designation for PXS‐5505 by FDA for treatment of myelofibrosis
PXS‐5505 has shown significant reductions in fibrosis in in‐vivo models of myelofibrosis

Pharmaxis Ltd (ASX:PXS) has been granted an orphan drug designation for its pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis by the US Food and Drug Administration (FDA).

PXS‐5505 is an oral drug that inhibits all lysyl oxidase family members (LOX, LOXL1, 2, 3 & 4).

The compound successfully cleared pre‐clinical safety including 6‐month toxicity studies and has shown significant reductions in fibrosis in in‐vivo models of myelofibrosis and other cancers.

PXS‐5505 has shown to be well tolerated in phase 1 single and multiple ascending dose studies in humans with an excellent pharmacokinetic and pharmacodynamic profile.

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

“Market with high unmet need and significant deal values”

Pharmaxis chief executive officer Gary Phillips said: “We are very pleased with the FDA orphan drug designation for PXS‐5505.

“Pharmaxis believes that the current treatments for myelofibrosis can be augmented by a pan‐LOX inhibitor and be disease modifying in a market with high unmet need and significant deal values for programs with clinical proof of concept.

“We expect to file an investigational new drug (IND) application with the FDA shortly and will provide an update on the clinical trial plans at that time.”

Current standard of care is inadequate

Myelofibrosis is a rare cancer in which normal bone marrow tissue is gradually replaced with a fibrous scar‐like material.

Over time, this leads to progressive bone marrow failure preventing the production of adequate numbers of red cells, white cells and platelets.

Myelofibrosis has a poor prognosis and limited therapeutic options.

Apart from a small group of patients eligible for stem cell transplantation, current standard of care are JAK1/2 inhibitors which provide mainly symptomatic relief but carry a risk of worsening blood cell counts.

A recent publication reported that Pharmaxis pan‐LOX inhibitor compounds significantly decreased the bone marrow fibrotic burden in two different models of primary myelofibrosis.

Quick facts: Pharmaxis Ltd

Price: 0.089 AUD

ASX:PXS
Market: ASX
Market Cap: $35.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Pharmaxis Ltd expects review of Bronchitol NDA to be completed by mid-2020

Pharmaxis Ltd (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) CEO Gary Phillips speaks to Proactive's Andrew Scott after it was announced its US licensee Chiesi Farmaceutici SpA filed a resubmission to the FDA for Bronchitol® . The move addresses issues raised by the US Food and Drug Administration (FDA)...

on 6/5/20

2 min read